Johnson & Johnson (JNJ) is a multinational American healthcare company that was founded in 1886. Headquartered in New Brunswick, New Jersey, the company is one of the world's most comprehensive and broadly based manufacturers of healthcare products. JNJ operates in three distinct sectors: Consumer, Pharmaceutical, and Medical Devices. Each of these segments plays a strategic role in maintaining the overall growth and profitability of the company.
The Consumer sector offers a broad array of products used in the baby care, oral care, skin care, wound care sectors, and a variety of over the counter pharmaceutical products. This area of the business appeals to individual consumers and contributes significantly to the company's total sales.
The Pharmaceutical sector is the largest segment and accounts for over half of the company’s revenue. Product categories include immunology, infectious diseases, neuroscience, oncology, cardiovascular, and metabolism. The company’s dedication to innovation and investment in research and development have allowed JNJ to consistently discover, develop, and launch many breakthrough medications.
The Medical Devices sector provides a range of products and solutions used by health care professionals in fields such as orthopedic, surgery, interventional solutions, and eye health. The firm's medical devices and diagnostics segment manufactures products including orthopedic products; cardiovascular care, diabetes care, infectious disease and diagnostics products.
Johnson & Johnson is globally recognized for its corporate citizenship and social responsibility. It has been listed on the Dow Jones Industrial Average since 1997 and holds Fortune 500 standing. The company’s long-term vision focuses on developing and delivering advanced health care solutions while maintaining strong ethical standards, transparency, and sustainability.
At the helm of Johnson & Johnson's success is its 'Credo,' a mission statement prioritizing the needs and well-being of the people they serve and the pursuit of science and innovation. Johnson & Johnson considers its employees as their greatest asset and places a significant emphasis on diversity and inclusion.
In recent years, the company has been in the spotlight for its role in developing one of the vaccines for COVID-19, highlighting the organization's steadfast commitment to global health. Overall, JNJ's well-diversified business model, robust product portfolio, focus on innovation, and commitment to societal responsibilities continue to drive its success in the global healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article identifies four healthcare dividend stocks—Bristol-Myers Squibb, Medtronic, AbbVie, and Johnson & Johnson—suitable for retirees due to their rising dividends, stability, and ability to withstand recessions. It details each company's yield, dividend safety, bull case, and risks, highlighting Bristol-Myers Squibb's leading yield of 4.03% and Johnson & Johnson's 64-year dividend raise streak. The piece emphasizes the balance between high current yield and consistent dividend growth for income investors.
Johnson & Johnson and Coca-Cola have both raised their dividends for 64 consecutive years. While Coca-Cola offers a higher yield, Johnson & Johnson's dividend streak appears safer due to a more comfortable payout ratio, consistent free cash flow coverage, and lower debt. Coca-Cola's dividend payout exceeded its free cash flow in fiscal years 2024 and 2025, although it projects a rebound in 2026.
Takeda has launched its narcolepsy therapy, Orzeyful, in the US following a swift review by the DEA, which classified it as Schedule IV due to its low potential for abuse. Orzeyful, an orexin agonist, is the first drug to target the underlying mechanism of narcolepsy type 1 (NT1) and is priced competitively at $16,500 per month, with analysts predicting peak sales between $2 billion and $5 billion annually. The drug's efficacy in improving a wide range of symptoms, as demonstrated in clinical trials, is expected to drive rapid adoption.
Amgen's stock is analyzed against its peers, including Johnson & Johnson, AbbVie, Merck, Pfizer, and Bristol Myers Squibb. The article highlights that Amgen, despite ranking second in revenue growth and operating margin among its peers, has a lower P/E ratio compared to Johnson & Johnson. This suggests that investors are paying less for Amgen's profit, even with its strong performance driven by a few fast-growing medicines and a raised 2026 revenue forecast.
This article highlights five Dividend Aristocrats® that have consistently raised their payouts for decades: Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Colgate-Palmolive. These companies are also Dividend Kings, having increased dividends for at least 50 years, thanks to their recession-resistant business models in consumer staples and healthcare. The piece suggests that focusing on these reliable dividend stocks can provide stability and help investors navigate volatile markets by offering a steady income stream.
This article compares the dividend prospects of Johnson & Johnson (JNJ) and Procter & Gamble (PG), both Dividend Kings with long histories of dividend raises. While J&J has more cushion in its free cash flow for dividend payments, P&G offers a higher forward yield and is projected to pay significantly more in dividends over the next decade, even if its dividend growth rate slows. The analysis suggests P&G's higher current payout makes it the preferred choice for income over the coming ten years.
RenaissanceRe Holdings Ltd. (NYSE:RNR) announced a quarterly dividend of $0.41 per share, equating to an annualized $1.64 and a 0.5% yield. The dividend, payable December 31 to shareholders of record December 15, appears well covered by earnings with a current payout ratio of 4.5% and an expected 3.9% next year. The company recently reported quarterly EPS of $12.71, surpassing consensus estimates, despite revenue of $1.69 billion falling short of expectations.
Alcon's third-quarter sales increased by 5% to $2.7 billion, but implantables experienced a 2% decline due to heightened competition in the US premium IOL market. To counter this, Alcon is relying on its new Vivity Pro lens, launching in January, an RxSight license, and the recent Neurotech acquisition to stimulate growth and outpace the estimated 3% market expansion. The company aims to restore growth in its implantables business after losing US premium intraocular lens share.
Johnson & Johnson's Innovative Medicine business, responsible for two-thirds of its third-quarter sales, saw its adjusted pretax margin fall to 35.4% from 44.3% despite a 7.9% operational sales growth. This decline is attributed to acquisition-related research expenses and transaction costs, along with a less profitable product mix and higher production costs. While sales continue to grow, the deals are expected to impact earnings per share negatively in both 2026 and 2027, leading to a high stock valuation that assumes these costs will fade and drug business growth continues.